SANTA CLARA (dpa-AFX) - Agilent Technologies Inc. (A) said that it has partnered with Akoya Biosciences Inc. (AKYA) to develop multiplex-immunohistochemistry diagnostic solutions for tissue analysis
The "Capillary Electrophoresis: Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The global market for Capillary Electrophoresis estimated at US$882.1
The US Food and Drug Administration (FDA) has approved Agilent Resolution ctDx FIRST as a companion diagnostic (CDx) to identify advanced non-small cell lung cancer (NSCLC) patients with KRAS G12C mutations who may benefit from treatment with KRAZATITM (adagrasib). Click to read more.
Agilent Technologies Inc. announced today that the U.S. Food and Drug Administration has approved Agilent Resolution ctDx FIRST as a companion diagnostic to identify advanced. | December 12, 2022